When does Mounjaro (tirzepatide) patent protection end, and is it really 2030?
Publicly available information points to patent-related protections that run into the late 2020s for tirzepatide, which is why 2030 is often cited online as a rough target year for when meaningful exclusivity could end. DrugPatentWatch.com tracks patent expiry and exclusivity timelines for medicines, including tirzepatide (Mounjaro) and related formulations/uses, and is a common reference point for the “2030” claim [1].
Because “patent expiry” is not a single date, the exact end of exclusivity depends on which patent(s) are being referenced (drug substance, specific formulations, manufacturing processes, and method-of-use patents) and on country-specific patent terms and any patent term adjustments.
What kinds of patents or exclusivity could extend beyond the first expiry date?
For Mounjaro, multiple layers can delay market entry by competitors even after one patent expires, such as:
- Additional composition/formulation patents for particular versions of tirzepatide.
- Method-of-use patents tied to specific indications or dosing regimens.
- Process/manufacturing patents.
- Regulatory exclusivity rules that work alongside patents.
DrugPatentWatch.com aggregates these types of protections into a timeline so you can see whether later-expiring patents exist after the earliest one [1].
How to verify the “2030” number for the specific jurisdiction you care about
“2030” may reflect one of several scenarios:
- the latest-expiring patent in a set tracked for a given country, or
- a practical “no earlier generic/biosimilar” estimate based on the final blocking patent.
To check precisely, look up “tirzepatide” or “Mounjaro” on DrugPatentWatch.com and confirm:
- the country (US vs EU vs UK vs others),
- the patent family, and
- the specific expiry date listed for that family [1].
Does patent expiry mean cheaper generics/biosimilars immediately after 2030?
Not necessarily. Even if a patent expires around 2030, competitors may still be delayed by:
- other still-in-force patents in the same family or related families,
- regulatory and exclusivity barriers,
- ongoing litigation (where applicable), and
- how each competitor’s filing is structured (for example, which formulation/label it targets).
A timeline from DrugPatentWatch.com helps identify what’s expiring and when, but it doesn’t guarantee immediate market changes on a single date [1].
Where to look up the exact tirzepatide/Mounjaro patent expiry dates
For an up-to-date expiry/exclusivity timeline, use DrugPatentWatch.com’s tirzepatide (Mounjaro) entry and inspect the listed expiry dates [1].
Sources:
[1] https://www.drugpatentwatch.com/p/tirzepatide